Assessment of Quinidine‐Induced Torsades de Pointes Risks Using a Whole‐Body Physiologically Based Pharmacokinetic Model Linked to Cardiac Ionic Current Inhibition

Abstract

The lethality of torsades de pointes (TdP) by drugs is one of main reasons that some drugs were withdrawn from the market. In order to assess drug‐induced TdP risks, a model of cardiac ionic current suppression in human ventricular myocytes (ToR‐ORd model), combined with the maximum effective free therapeutic plasma concentration or the maximum effective free therapeutic myocyte concentration was often used, with the latter proved to be more relevant and more accurate. We aimed to develop a whole‐body physiologically‐based pharmacokinetic (PBPK) model, incorporated with a human cardiomyocyte pharmacodynamic (PD) model, to provide a comprehensive assessment of drug‐induced TdP risks in normal and specific scenarios. Quinidine served as an example to validate the PBPK‐PD model via predicting plasma quinidine concentrations and quinidine‐induced changes in QT interval (ΔQTc). The predicted plasma quinidine concentrations and ΔQTc values following oral administration or intravenous administration of quinidine were comparable to clinic observations. Visual predictive checks showed that most of the observed plasma concentrations and ΔQTc values fell within the 5th and 95th percentiles of simulations. The validated PBPK‐PD model was further applied to assess the TdP risks using frequencies of early afterdepolarization and long‐QT syndrome occurrence in 4 scenarios, such as therapeutic dose, supra‐therapeutic dose, alkalosis, and hyperkalemia in 200 human subjects. In conclusion, the developed PBPK‐PD model may be applied to predict the quinidine pharmacokinetics and quinidine‐induced TdP risks in healthy subjects, but also simulate quinidine‐induced TdP risks under disease conditions, such as hypokalemia and alkalosis.